Status: Not yet recruiting
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.
Participants needed: 114
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Hefei Xinzhu Biological Technology Co., Ltd.Updated: Jun 12, 2026Locations: 6
Eligibility criteria
Willingness to voluntarily participate in the study and provide written informed... [+10]
Presence of unstable central nervous system (CNS) metastases or concurrent prima... [+17]